Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study.

ABSTRACT:

Background

Second-line options for biliary tract cancer (BTC) are limited. While nab-paclitaxel has demonstrated certain antitumor activity, evidence remains scarce. With gemcitabine-cisplatin plus anti-programmed death-ligand 1 (PD-(L)1) established as the first-line standard, the benefit of second-line immunotherapy-especially in patients without prior anti-PD-(L)1 exposure-remains unclear.

Objectives

To evaluate the efficacy and safety of nab-paclitaxel-based second-line treatments for advanced BTC, and compare outcomes between regimens with and without anti-PD-(L)1.

Design

This is a real-world retrospective study.

Methods

This study reviewed BTC patients who received second-line nab-paclitaxel-based therapy at West China Hospital between August 2018 and Aug

SUBMITTER: Zhou N 

PROVIDER: S-EPMC12663050 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature